
A 2A1-LC-Cys205ins-mc-vc-PAB-MMAE
AU
0.80
0.60
0.40
0.20
0.00
-0.20
3.818
6.241
8.329
9.391
10.437
2.00
4.00
6.00
8.00
10.00
12.00
14.00

图 1


B 2A1-LC-Cys206ins-mc-vc-PAB-MMAE
AU
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
-0.10
3.817
5.860
7.488
9.803
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
分钟

图 2


C 2A1-HC-Cys439ins-mc-vc-PAB-MMAE
AU
分钟
8.067
11.946
14.081

图 3


D 4E1-LC-Cys205ins-mc-vc-PAB-MMAE
AU
分钟
4.370
6.239
8.219
9.468

图 4


E 4E1-LC-Cys206ins-mc-vc-PAB-MMAE
AU
0.040
0.030
0.020
0.010
0.000
4.402
5.759
7.556
9.240
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.0
分钟

图 5


F 4E1-HC-Cys439ins-mc-vc-PAB-MMAE
AU
0.010
0.008
0.006
0.004
0.002
0.000
-0.002
-0.004
4.820
8.744
10.342
12.690
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
分钟

图 6


G 4D3-LC-Cys205ins-mc-vc-PAB-MMAE
AU
分钟
3.613
6.330
8.507
9.977

图 7


H 4D3-LC-Cys206ins-mc-vc-PAB-MMAE
AU
分钟
3.961
5.983
7.968
10.059

图 8


18.949
HC 1 drug
HC 0 drug
19.811
AU
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
22.00
24.00
min

图 9


第0天
第7天
第14天
第21
第29天

图 10



图 11



图 12


第0天
第7天
第14天
第21天
第29天

图 13


EGFR-Ⅷ Binding ELISA
2.5
2.0
1.5
1.0
0.5
0.0
450nm
10-6
10-4
10-2
100
102
Ab(ug/ml)
2A1
2A1-LC-V205C
2A1-LC-Cys205ins
2A1-LC-Cys206ins
2A1-HC-Cys439ins

图 14


c-Met Binding ELISA
OD450nm
2.0
1.5
1.0
0.5
0.0
10-4
10-2
100
102
ug/ml
4E1
4E1-LC-Cys205ins-MVPM
4E1-LC-Cys206ins-MVPM
4E1-HC-Cys439ins-MVPM

图 15


Trop2 Binding ELISA
OD450
2.5
2.0
1.5
1.0
0.5
0.0
0.0001
0.01
1
100
Ab (ug/ml)
4D3
4D3-HC-Cys439ins-MVPM
4D3-LC-Cys205ins-MVPM
4D3-LC-Cys206ins-MVPM

图 16


% of control cell viability
Compound Concentration, log [nM]
2A1-LC-V205C-mc-vc-PAB-MMAE (IC50=91.26nM)
2A1-LC-Cys205ins-mc-vc-PAB-MMAE (IC50=133.67nM)
2A1-LC-Cys206ins-mc-vc-PAB-MMAE (IC50=179.26nM)
2A1-HC-Cys439ins-mc-vc-PAB-MMAE (IC50=26.62nM)

图 17


% of control cell viability
Compound Concentration, log [nM]
2A1-LC-V205C-mc-vc-PAB-MMAE (IC50=296.11nM)
2A1-LC-Cys205ins-mc-vc-PAB-MMAE (IC50=492.14nM)
2A1-LC-Cys206ins-mc-vc-PAB-MMAE (IC50=457.48nM)
2A1-HC-Cys439ins-mc-vc-PAB-MMAE (IC50=118.52nM)

图 18


Effect of TDC on U87-MG cell viability
% signal compared with no drug
Compound Concentration, log [nM]
4E1-HC-Cys439ins-MVPM IC50=7.41nM
4E1-LC-Cys205ins-MVPM IC50=120.50nM
4E1-LC-Cys206ins-MVPM IC50=79.57nM
4E1 IC50>1000nM

图 19


Effect of TDC on BXPC-3 cell viability
%signal compared with no drug
120
100
80
60
40
20
0
-4
-2
0
2
4
Compound Concentration, log [nM]
4D3 IC50>1000nM
4D3-HC-Cys439ins-MVPM IC50=0.23nM
4D3-LC-Cys205ins-MVPM IC50=0.38nM
4D3-LC-Cys206ins-MVPM IC50=0.45nM

图 20


A 4D3-HC-Cys439ins-mc-vc-PAB-MMAE
孵育 72h
孵育 0h

图 21


孵育0h
B 4D3-LC-Cys205ins-mc-vc-PAB-MMAE
孵育72h

图 22


孵育0h
C 4D3-LC-Cys206ins-mc-vc-PAB-MMAE
孵育72h

图 23


← 孵育 0h
D 4E1-LC-Cys205ins-mc-vc-PAB-MMAE
孵育 72h→

图 24


← 孵育 0h
E 4E1-LC-Cys206ins-mc-vc-PAB-MMAE
孵育 72h →

图 25


F 4E1-HC-Cys439ins-mc-vc-PAB-MMAE
孵育 0h
孵育 72h

图 26


A . Antitumor Acitivity of Trop2 ADC as Single Agents in the Treatment of BXPC-3 Human Pancreatic Cancer Xenograft Model
Tumor Volume mm3
1400
1200
1000
800
600
400
0
5
10
15
Day
Vehicle
4D3-HC-Cys439ins-MVPM(5mg/kg)
4D3-LC-Cys205ins-MVPM(5mg/kg)
4D3-LC-Cys206ins-MVPM(5mg/kg)
mAb(5mg/kg)

图 27


B .The Body Weight Changes of the Mice in the Different Groups
Vehicle
4D3-HC-Cys439ins-MVPM(5mg/kg)
4D3-LC-Cys205ins-MVPM(5mg/kg)
4D3-LC-Cys206ins-MVPM(5mg/kg)
mAb(5mg/kg)
Tumor Volume mm3
25
20
15
0
5
10
15
Day

图 28